Cell and Gene Therapy East Asia 2025

Novel manufacturing strategies for commercialization

Regional leaders will explore commercialization, regulation, and collaboration in the development of cell and gene therapies (CGTs). A panel including Ryu Kang (CSO, Vaxcell-Bio), Kenji Nakamaru (VP, Head of R&D, Optieum Biotechnologies), and Phil Huang (Technical Director, Stemcyte) will showcase how East Asia’s innovation hubs can drive therapy development and commercialization, while addressing regional supply chain challenges and fostering cross-border collaboration in research, clinical trials, and patient access. Furthermore, Bryan Choi (ISCT Asia Regional Vice-President and Professor, Inha University) will present on Asia’s evolving regulatory landscape and infrastructure supporting CGT growth. Phil Huang will highlight REGENECYTE, showcasing the expanding potential of cord blood stem cell therapy beyond oncology.

Scaling up CGT manufacturing

The conference will also highlight advancements in scalable manufacturing for next-generation CGTs. KwangJun Yoon (Managing Director, CHA Biotech) will share strategies for risk management and regulatory alignment, while Sungjun Yoon (CEO, Fortuga Bio) will explore the clinical translation of dendritic cell immunotherapies. Kazuchika Furuishi (Board of Director, CellFiber) will discuss innovations in encapsulation technology and overcoming manufacturing challenges to ensure quality and GMP compliance.

CAR-T & CAR-NK cell therapies in oncology

This event will also cover innovative CAR-T and immune cell therapies for solid tumors and hematologic malignancies. Lee Heon Ju (CEO, CarBio Therapeutics) will present innovative fifth-generation CAR-T platform technology targeting challenging solid tumors. Kenji Nakamaru (VP and Head of R&D, Optieum Biotechnologies) will discuss scFv-CAR optimization to enhance T cell function. Manh-Cuong Vo (General Manager of R&D, Vaxcell-Bio) will highlight NK cell and CAR-based therapies showing promising clinical activity. Cheng-Yi Jerry Kuo (Vice General Manager, UWELL Biopharma) will cover clinical development and trials of CAR-T cell therapies for blood cancers.

Innovations in gene editing & delivery systems

The conference will highlight innovations in gene editing, delivery systems, and extracellular vesicle (EV) therapeutics. Jaesuk Lee (CSO, nSAGE) will present the discovery and engineering of a novel Cas12a base editor with enhanced efficiency and multiplex capabilities. Seokjoong Kim (CSO, GenEdit) will discuss advances in polymer-based delivery technologies for genomic medicine. Chaemin Lim (Assistant Professor, CHA University) will explore therapeutic engineering of EVs, focusing on cell source screening, functional enhancement, and drug formulation strategies to boost stability and efficacy.

Cell and Gene Therapy East Asia 2025 is set to be a pivotal event showcasing the latest breakthroughs in gene-modified therapies, scalable manufacturing, and regulatory innovation across the region. Bringing together top industry leaders, researchers, and regulators, the conference will explore strategies to accelerate commercialization, overcome manufacturing challenges, and foster cross-border collaboration. Key sessions will highlight cutting-edge CAR-T and immune cell therapies, advanced gene editing tools, and novel delivery platforms, offering unparalleled insights into the future of cell and gene therapy development and precision medicine in East Asia.

As a reader of Cell & Gene Therapy Insights, you’re entitled to a 15% discount on delegate tickets—just use the code BIOINSIGHTS. You can find out more about the Cell and Gene Therapy East Asia 2025 events here.

Additionally, to find out what other cell and gene therapy events are upcoming, you can find our online Events Calendar here.